SummaryTrump touted a new TrumpRx deal promising obesity drugs like Wegovy and Zepbound for about $250 monthly, but experts warn the plan is unclear, includes unapproved products, and only discounts low doses. Since effective treatment needs higher doses, patients may ultimately pay far more than advertised in the long run, too.